Systematic Review of Thalidomide for Angiodysplasia-Related GI Bleeding

265 patients with a median age of 63.5 years were included in this systematic review evaluating thalidomide for gastrointestinal bleeding from angiodysplasia. The document, authored by Junaid Khan and last updated in March 2026, synthesizes evidence from six clinical studies published between 1994 and 2024. It reports on clinical outcomes, response rates, and adverse effects associated with thalidomide treatment.

Use Cases

• Conducting a meta-analysis on thalidomide response rates based on reported hemoglobin improvement and bleeding episode reduction.
• Comparing adverse effect profiles of thalidomide treatment based on reported side effects like constipation and peripheral neuropathy.
• Analyzing the heterogeneity in treatment outcomes based on study design variations (RCTs, observational studies, case series) mentioned in the review.

Strengths

• Includes data from 265 patients aggregated from six clinical studies.
• Covers literature from a defined time range (1994 to February 2024).
• Reports specific response rates (e.g., 84%, 68.6%) and risk differences with confidence intervals.

Limitations

• The primary data is a synthesized review document (2.5 MB DOCX), not the raw patient-level dataset.
• Row count for underlying data is unknown, which may limit suitability assessment for statistical modeling.
• Column-level documentation for any underlying tabular data is absent; field semantics must be inferred after download.

Provenance

Source

Junaid Khan via figshare.

Collection Method

Systematic literature review conducted across PubMed, Embase, Scopus, and CINAHL.

Time Range

Literature covered from 1994 to February 16, 2024.

Freshness

Last updated 2026-03-18 07:35:16.